TABLE OF CONTENTS

4 WELCOME LETTER
6 MEMBERSHIP
8 WEBSITE INTEGRATION
10 EDUCATION & CONFERENCES
12 WCLC 2020
14 SCIENTIFIC AFFAIRS
20 JTO AND JTO CRR
22 PATIENT ADVOCACY
26 WEBINARS
28 CORPORATE RELATIONS
30 INTERNATIONAL LUNG CANCER FOUNDATION
32 2020 DONORS
34 BOARD OF DIRECTORS AND STAFF
This year has been marked by opportunities, challenges, and change. It has compelled us to rethink time-tested approaches and norms while forcing us to adapt, learn new skills, and adjust our behaviors. The SARS-CoV-2 pandemic, or COVID-19, has touched every aspect of our lives, both personally and professionally. The IASLC has been impacted by the pandemic as well. It has affected our work—from member engagement, to education and meetings, to communications, scientific projects, our finances, and operations. Just as our members have risen to the challenge posed by this historic pandemic, whether through patient care or research, the IASLC has devoted itself to making the necessary adjustments caused by the pandemic while also preparing for the future.

Early in 2020, as the pandemic was taking hold, the IASLC Board of Directors and Leadership adopted a management approach to meet this moment. By leveraging the strengths and the 45-year history of the society, we vowed to maintain a long-term perspective when making decisions. We committed ourselves to producing relevant content offerings and value for our members and the field. We adjusted quickly to diversify how that content was delivered via new modalities and we continued to make the key investments as outlined in the organization’s strategic plan. But most important was the continued health and safety of our members, stakeholders, partners, and staff.

These dynamics led us to reconsider how we delivered our 2020 meetings. In October, we held the IASLC 2020 Hot Topic: Liquid Biopsy Meeting and the 2020 North America Conference on Lung Cancer Meeting in virtual formats. IASLC faculty presented the advances in liquid biopsy technology and shared lively discussions on clinical applications. More than 450 individuals from over 40 countries participated in the virtual meeting. The 2020 North America Conference on Lung Cancer was also a resounding success with 600+ delegates and experts from more than 35 countries participating. The fully virtual meeting was an opportunity for faculty to showcase novel research while facilitating rich discussions that will shape the future of treatment in lung cancer and other thoracic malignancies. We also made the difficult, yet necessary, decision to postpone the 2020 IASLC World Conference on Lung Cancer to January 2021 and convert it to a worldwide virtual event.

As we conclude 2020 and given the status of the pandemic, we are already making plans to conduct all of our 2021 meetings as worldwide virtual events. As circumstances improve, we will add live, in-person components to our virtual meetings.

The IASLC generated relevant content and engagement through myriad means in 2020. The *Journal of Thoracic Oncology*, with its Impact Factor of 13.357, is now among the top 5 percent of all oncology journals and is the leading thoracic oncology-focused journal. We also launched the *JTO Clinical and Research Reports* (JTO CRR) in 2020. As an open-access journal, the JTO CRR publishes a range of manuscripts from subset analyses of published trials to high-quality case reports.

As part of our collaborative partnership with the Lung Ambition Alliance, the IASLC continued its leadership of the IASLC Staging Project in preparation for the 9th edition, the Early Lung Imaging Confederation (ELIC), and the Major Pathological Response projects. In 2020, as a founding partner of the Alliance, the IASLC also led the way to expanding the Alliance with five additional project partners.

Other important scientific initiatives include our work within ASCO’s Quality Oncology Practice Initiative where Brazilian and Spanish oncology practices can now access and improve their quality of care by participating in the QOPI lung cancer track. We are also engaged in CancerLinQ, a health information technology platform to enhance and improve the understanding and treatment of cancer. You can learn about this work here. The IASLC Tobacco Control and Smoking Cessation Committee has continued to advance our message found in the IASLC Smoking Cessation Declaration. The Nurses and Allied Health Professionals Committee continued the important work of developing educational materials and webinars, contributing articles to the ILCN and creating early-career opportunities to close the educational gaps in thoracic oncology. The IASLC, through the work of the Pathology Committee, also released the IASLC *Atlas of Diagnostic Immunohistochemistry* (IHC), to provide pathologists with up-to-date information on when to use IHC. You can order your copy of the IHC Atlas here.
The IASLC’s commitment to people diagnosed with thoracic cancers was further enhanced in 2020 as we launched the second annual class of the Supportive Training for Advocates on Research & Science (STARS) program. Through STARS, prospective Patient Research Advocates (PRAs) are educated about how to read and interpret research articles and presentations, and are trained to communicate effectively with both the research and patient communities.

We were also excited to have launched a new Association Management System and the new IASLC website in 2020. These two significant infrastructure improvements will enhance the member experience, create streamlined communication with our members, and foster a more user-friendly experience for everyone. We have also successfully digitized the Lung Cancer News within our website. We encourage you to take a look at the new IASLC.org.

Finally, 2020 also presented multiple examples of persistent social inequity and injustice. The death of George Floyd and the ensuing demonstrations in the U.S. were reported widely around the globe. These incidents have called on our humanity and commitment to justice. As a truly international organization with members in 103 countries, the IASLC stated our shared resolve toward equity and a renewed commitment to foster a culture of respect. Read the IASLC’s Statement on Injustice.

We entered this pandemic period in a strong financial and operational position, poised to tackle its uncertainties and risks. The decisions we have made are intended to keep our community safe, to enhance the society’s relevant offerings, and to position ourselves for a successful future. The key to meeting this moment has, of course, been you, our members. As we turn the calendar to 2021, please stay passionate about your work to advance lung cancer care and your involvement with the IASLC. Whether you are a scientist, clinician, nurse, or advocate, your contributions are fundamentally important in improving clinical outcomes and quality of life for patients and their loved ones. The IASLC is proud to be a partner, resource, and home for this global community of professionals. We look forward to our future collaborations, achievements and breakthroughs, as we work together to Conquer Thoracic Cancers Worldwide.

With our best wishes,

Dr. Tetsuya Mitsudomi, IASLC President &
Dave Mesko, IASLC Chief Executive Officer

Dr. Tetsuya Mitsudomi
Osaka, Japan
IASLC’s International and Multidisciplinary Membership

The foundation of the IASLC has always been its multidisciplinary and international membership base. As the outbreak of COVID-19 spread around the globe, IASLC members continued working in incredibly difficult circumstances to contain the outbreak and prevent further loss of life. By pooling our collective knowledge and expertise, the IASLC community worked together to create the IASLC’s Guide to COVID-19 and Lung Cancer, highlighting best practices, personal feedback, professional articles, tools, podcasts, webinars, and other educational opportunities for members to access during this difficult time.

Despite the worldwide focus on COVID-19, IASLC members from all corners of the world continued to push scientific advancements in multiple areas. For more than 45 years, IASLC members have collaborated globally to advance our mission of conquering thoracic cancers worldwide. By participating in educational events such as the IASLC’s 2020 Hot Topic Meeting: Liquid Biopsy, the 2020 North America Conference on Lung Cancer, and the 2020 World Conference on Lung Cancer | Singapore, lung cancer specialists gained access to the latest research and scientific findings in thoracic oncology—further advancing their profession through education and development opportunities.

This year, the IASLC invested in new technologies and infrastructure to enhance the IASLC member experience and has launched an entirely new IASLC database, member portal, and website. The new IASLC member portal is fully customized, easy-to-navigate, and is a fully comprehensive hub where members can access key member benefits including the Journal of Thoracic Oncology, the virtual library, and the IASLC member directory. New functionality in the portal allows members to renew their membership with additional payment methods including PayPal, American Express, and JCB, and securely displays their profile information for easy updates and features like membership auto-renewal and quick check-out in the store.

Comprising every specialty in lung cancer, our committee members and their contributions are at the heart of the society. As part of our 13 committees, ranging from patient advocacy to our scientific committees and more, IASLC committee members continue to contribute their specialized skills and talents to help shape the work of the organization, develop educational content, plan annual meetings, contribute to publications authored by the IASLC, and more. This year, the IASLC Pathology Committee released the new Atlas of Diagnostic Immunohistochemistry. This Atlas plays a key role in the diagnosis of thoracic tumors and provides pathologists up-to-date information to help them determine when to use IHC, and how to correctly interpret the results. Additionally, the IASLC Tobacco Control and Smoking Cessation Committee developed “Tobacco Control Moments” which were shared at the 2020 North America Conference on Lung Cancer. These were short and focused video updates on key topics to provide relevant information to healthcare providers.

Regardless of your career phase, specialty, or geographic location, the IASLC is your hub for education and collaboration. The IASLC continues to put our members first—so they can go above and beyond for patients—by offering discounted registration fees to meetings and educational events, complimentary access to the JTO, and discounted publication fees for the newest open-access IASLC journal, JTO Clinical and Research Reports (JTO CRR). Another great member benefit is the IASLC Online Member Directory which allows members to directly connect and collaborate. In addition, the IASLC is proud to offer members access to free continuing medical education opportunities, volunteer opportunities, and more.
Members by Country/Region:

- **Europe**: 39 countries, 22% of total members
- **Asia**: 28 countries, 27% of total members
- **North America**: 2 countries, 37% of total members
- **Latin America**: 13 countries, 9% of total members
- **Africa**: 1 country, 1% of total members
- **Australia**: 1 country, 4% of total members

Top 10 Countries for Membership:

- USA
- Japan
- China
- Canada
- Australia
- UK
- Brazil
- Republic of Korea
- Mexico
- India

Members by Age:

- **24 or Below**: 1%
- **25-34**: 17%
- **35-44**: 29%
- **45-54**: 25%
- **55-64**: 19%
- **65-74**: 7%
- **75+**: 1%

Members by Primary Specialty:

- **Medical Oncology**: 33%
- **Thoracic Surgery**: 15%
- **Pulmonary Medicine**: 11%
- **Other/Unknown**: 9%
- **Cancer Research/Basic Sciences**: 8%
- **Radiation Oncology**: 7%
- **Pathology**: 6%
- **Patient Advocacy**: 4%
- **Biotech/Pharmaceutical Industry**: 2%
- **Nursing**: 2%
- **Diagnostic Radiology**: 1%
- **Pharmacy**: 1%
- **Biostatistics**: 1%

* Other includes: Hematology, Pharmacy, Smoking Cessation, Resp. Therapy/Physiotherapy, Patient/Survivors, Caregivers and Unknown.

Location-Professional Activity/Practice:

- **Academic Medical Center/University**: 52%
- **Other/Unknown**: 11%
- **Pharmaceutical/Biotech**: 9%
- **Private Practice (Office)**: 4%
- **Private Practice (Hospital)**: 4%
- **Training Program**: 3%
- **Nonprofit or Advocacy**: 2%
- **Laboratory Research**: 2%
- **Government Agency**: 1%
- **Administration**: 1%
Never before has technology mattered more to our daily lives and professional communications. Recognizing the many demands placed on our members’ time, the IASLC has made upgrades to its member database and website. Members can now easily access their account data and their membership benefits via quick links on the home page of IASLC.org. Members and nonmembers can view and search for more timely and relevant news on every page of the site. Articles from the Journal of Thoracic Oncology and JTO Clinical Research Reports are available on the new IASLC.org, organized by theme and relevance. And, meetings and webinars are now searchable in numerous ways, including by presence of CME-accreditation.

In the new customized and easy-to-navigate member portal, IASLC members can now renew their memberships and make donations to the ILCF with additional payment options including PayPal, American Express, and JCB, among others. Memberships can also be set to securely auto-renew immediately upon expiration, ensuring ease for users and continuous access to member benefits year after year.

Members can now access a clear and comprehensive view of their user profile and can easily update contact information including social media accounts. They also can directly and easily connect with colleagues around the globe utilizing the improved IASLC member directory with direct messaging capabilities.

While patient advocates have long been recognized as contributing members of the association, the IASLC was pleased to announce the formation of a specific membership category in 2020: Patient Advocate Membership. This membership is intended for individuals who work for a patient advocacy organization or are professionally involved with patient advocacy efforts.

The IASLC also introduced new technology tools to enhance committee engagement. IASLC committee members can now utilize new private Community Groups, found within the IASLC member portal, to share files, post secure updates, and easily keep up-to-date with committee activity.
Publications, resources, and guidelines can be quickly and easily accessed from the updated IASLC Website and IASLC Store. Members and nonmembers alike can explore an expansive catalog of Atlases, staging resources, new and archived guidelines, and materials for patients and providers.

Whether you are an early-career physician looking for grant and mentoring opportunities, or a patient advocate looking to take the next step toward communicating more effectively about lung cancer research, there are unique and robust offerings for you.

We at the IASLC are excited for our stakeholders to explore the new offerings and to provide feedback. For timely and relevant news and association information, visit IASLC.org. To go directly to the member portal, visit my.iaslc.org. Contact us with any questions or comments at membership@iaslc.org.
This year it was imperative for the IASLC to adapt its live meetings to virtual conferences, given the serious public health concerns and restrictions on travel and in-person gatherings. As a result, the IASLC pivoted to a fully online platform with pre-recorded sessions, live, and on-demand content.

The IASLC received positive feedback from attendees during our initial online offerings, with specific recognition of the innovative content and live panel discussions, and Q&A opportunities. As the year progressed, the IASLC Program Committees continued to place a high priority on interactivity in the virtual environment, such as live Q&A; live tumor board panels with break out rooms for discussions; networking lounges; enhanced chat functions with delegates, faculty, patients, and exhibitors; conversation boards; and live poster discussions. While we missed seeing faculty, delegates, and friends in person, going virtual allowed the IASLC to provide a global platform for even greater attendance and accessibility.

IASLC 2020 CONFERENCES AND EVENTS

› 2020 SIXTH AACR-IASLC INTERNATIONAL JOINT CONFERENCE | In-person Event: San Diego, California, USA | January 2020

In conjunction with the American Association for Cancer Research (AACR), the IASLC held the sixth biennial international conference on lung cancer science. Nearly 250 attendees from diverse fields (physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research) discussed recent advances and established new collaborations. Session topics included preneoplasia and early detection, immunotherapy, molecular targets, drug resistance, tumor progression, and metastasis.

› IASLC 2020 LUNG CANCER TARGETED THERAPIES MEETING | In-person Event: Santa Monica, California, USA | February 2020

The IASLC 2020 Targeted Therapies of Lung Cancer Meeting (TTLC20) was held at the Fairmont Miramar Hotel in Santa Monica, California from February 19-22, 2020. Meeting Chairs Drs. Paul A. Bunn, Jr., Roy Herbst, Leora Horn, and Suresh Ramalingam welcomed more than 700 participants from 15 countries to share information about ongoing clinical trials of the newest therapies for lung cancer. Participants were encouraged to actively participate in discussions and engage with industry supporters. Presenters summarized the data on relevant targets for new therapies and shared data on preclinical and early clinical data for each of the drugs directed against these targets. At the TTLC20, 36 abstract submissions were received, 33 education awards were presented, and 13 exhibitors participated in the meeting, with Genentech as the Diamond sponsor.
› **FDA/CDER-AACR-IASLC WORKSHOP TO ADDRESS THE CRITICALITY OF TOBACCO USE ASSESSMENT IN ONCOLOGY THERAPEUTIC TRIALS | In-person Event: Silver Springs, Maryland, USA | February 2020**

This meeting provided a forum for open discussion between the public, academia, industry, FDA, and other stakeholders to improve the public understanding of the significance of persistent tobacco use on outcomes, clinical trials that test therapies for cancer, cardiovascular, and pulmonary diseases. During this meeting, the FDA, AACR, and the IASLC expressed a willingness to leverage their combined strengths to develop substantive activities to address the criticality of assessing the use of tobacco in oncology clinical trials.

› **IASLC 2020 WCLC VIRTUAL PRESIDENTIAL SYMPOSIUM | Worldwide Virtual Event | August 2020**

The IASLC presented practice-changing studies and recent advances in thoracic oncology at the IASLC WCLC 2020 Virtual Presidential Symposium (VPS) on August 8, 2020. With 2,770 registrants, the VPS served as a prelude to the innovative research that was presented at the WCLC 2020 worldwide virtual event in January 2021.

› **IASLC 2020 HOT TOPIC MEETING: LIQUID BIOPSY | Worldwide Virtual Event | October 2020**

The state-of-the-art IASLC 2020 Hot Topic Meeting: Liquid Biopsy gathered international and multidisciplinary experts in the field of liquid biopsy in lung cancer to present and discuss recent advances in liquid biopsy technology and clinical applications. The meeting Chairs, Drs. Maria Arcila, David Gandara, and Christian Rolfo organized a two-day program with an internationally renowned faculty. Topics included the basics of liquid biopsy to real world challenges for a worldwide application, a molecular tumor board, as well as relevant clinical trials, and updates on the FDA perspective on the use of Liquid Biopsy in NSCLC, and data leveraging ctDNA to detect minimal residual disease following surgery. With more than 500 registrants from nearly 50 countries, 42 abstracts submitted, and 8 industry sponsors, this worldwide conference was a milestone accomplishment for the IASLC.

› **IASLC 2020 NORTH AMERICA CONFERENCE ON LUNG CANCER | Worldwide Virtual Event | October 2020**

The 2020 North America Conference on Lung Cancer, chaired by Drs. Julie Brahmer, Jessica Donington, Heather Wakelee, and Everett Vokes, provided wide-ranging and multidisciplinary content including keynote lectures, mini oral, and poster presentations, affording delegates the opportunity to learn, share knowledge, and network with delegates from around the world. With more than 600 attendees from 43 countries, delegates enjoyed research from 108 submitted abstracts, and booths from 17 industry sponsors.

The NACLC featured presentations from distinguished faculty on novel early-stage disease solutions and reviews of clinical trials and presentations on first-line targeted therapy for patients with rare driver mutations. Stigma presentations, along with the role of surgery in oligometastatic lung cancer, were also featured. The IASLC also incorporated patient perspective videos and showcased brief educational presentations by members of the Tobacco Control and Smoking Cessation Committee highlighting the importance of delivering smoking cessation services in a telehealth environment, lung cancer screening, and smoking cessation clinical trials.
The IASLC made the early and intentional decision to move the 2020 World Conference on Lung Cancer (WCLC 2020) to January 2021 in hopes that a live meeting would still be possible. When it became clear that the meeting would not be possible in early 2021, the IASLC leadership and Board of Directors made the difficult, but unavoidable, decision to pivot to a fully virtual meeting.

After a long-standing tradition of holding a live in-person WCLC meeting in different locations all over the world, the IASLC was looking forward to holding the WCLC in Singapore and had already begun planning with the Conference Chairs. Despite the delivery format change, the WCLC Conference Chairs, Drs. Yi-Long Wu, Daniel Tan, and Ross Soo continued the IASLC’s tradition of delivering a top-notch educational program marked by practice-changing abstracts.

**WCLC 2020 AWARD WINNERS: Recognizing Excellence in the Lung Cancer Field**

**2020 Distinguished Service Awards:**

In addition to serving as a source for exceptional education, the 2020 WCLC also represents an opportunity to recognize excellence in the field of lung cancer research. Each year, the association distributes awards that recognize lifetime achievement in specific areas of practice, with the most significant honors—the IASLC Distinguished Service Awards—being distributed during the WCLC Opening Ceremony.

<table>
<thead>
<tr>
<th>Award Category</th>
<th>Recipient</th>
<th>Institution and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020 Adi F. Gazdar</td>
<td>Alex A. Adjei, MD, PhD</td>
<td>Professor of Oncology and Pharmacology Consultant, Medical Oncology Mayo Clinic, Rochester, MN, USA</td>
</tr>
<tr>
<td>IASLC Merit Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020 Paul A. Bunn, Jr.</td>
<td>Joan H. Schiller, MD</td>
<td>Medical Oncology Specialist, Inova Fairfax Medical Campus, Fairfax, VA, USA</td>
</tr>
<tr>
<td>Scientific Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020 Joseph W. Cullen</td>
<td>Pan-Chyr Yang, MD, PhD</td>
<td>National Taiwan University College of Medicine Professor, Department of Internal Medicine, Taipei City, Taiwan</td>
</tr>
<tr>
<td>Prevention/Early Detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020 Mary J. Matthews</td>
<td>Caroline Dive, CBE, PhD, FBPhS, FMedSci</td>
<td>Professor of Cancer Pharmacology, University of Manchester, United Kingdom</td>
</tr>
<tr>
<td>Pathology/Translational</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Award</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2020 LECTURESHIP AWARDS

2020 ROBERT J. GINSBERG LECTURESHIP AWARD FOR SURGERY
Eric Lim, MD, MSc, FRCS, Professor of Thoracic Surgery, The Royal Brompton Hospital, London, United Kingdom

2020 CLIFTON F. MOUNTAIN LECTURESHIP AWARD FOR STAGING
Enrico Ruffini, MD, Department of Thoracic Surgery University of Torino, Torino, Italy

2020 IASLC LECTURESHIP AWARD FOR TOBACCO CONTROL AND SMOKING CESSIONATION
Wanda de Kanter, MD, Consultant, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

2020 JAMES D. COX LECTURESHIP AWARD FOR RADIATION
Walter J. Curran, Jr., MD, FACP, FASCO, Lawrence W. Davis Chair of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, USA

2020 FRED R. HIRSCH LECTURESHIP AWARD FOR TRANSLATIONAL RESEARCH
Sanja Dacic, MD, PhD, Professor of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

2020 TSUGUO NARUKE LECTURESHIP AWARD FOR SURGERY
Samina Park, MD, Seoul National University Hospital, Seoul, Republic of Korea

2020 DANIEL C. IHDE LECTURESHIP AWARD FOR MEDICAL ONCOLOGY
Myung-Ju Ahn, MD, Samsung Medical Center, Seoul, Republic of Korea

2020 IASLC LECTURESHIP AWARD FOR NURSES AND ALLIED HEALTH PROFESSIONALS
Mary Duffy, RSCN, Peter MacCallum Cancer Centre, Lung Nurse Coordinator, Melbourne, Victoria, Australia

2020 HEINE H. HANSON LECTURESHIP AWARD FOR SMALL CELL LUNG CANCER
Lauren Byers, MD, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center Houston, Texas, USA

Learn more about the IASLC’s Distinguished Service Award Winners, Lectureship Award Winners, and Advocacy Winners.

Dr. Hidetoshi Hayashi
Osaka, Japan

WCLC MEDIA COVERAGE

32 NEWS RELEASES ISSUED
117 REMOTE JOURNALISTS
3,734 STORIES IN SPANISH MEDIA OUTLETS
3,683 STORIES IN ASIAN MEDIA OUTLETS
65,600 TOTAL MEDIA MENTIONS
50,624 VIEWS OF IASLC NEWS RELEASES ON EUREKALERT BY JOURNALISTS
3 PRESS BRIEFINGS
500+ NEW FOLLOWERS ADDED ACROSS ALL SOCIAL PLATFORMS
123 TOTAL NUMBER OF COUNTRIES IN WHICH MEETING WAS COVERED

NUMBER OF INVITED SPEAKERS
240

NUMBER OF PLENARY SPEAKERS
43

INVITED SESSION CHAIRS
46

INVITED SPEAKERS
150

DISCUSSANTS
45

NUMBER OF POSTER PRESENTATIONS
963 1,500+ 93

ACCEPTED POSTERS E-POSTERS FEATURED POSTERS

NUMBER OF ORAL ABSTRACT SESSIONS
11 SESSIONS 45 ABSTRACTS

NUMBER OF MINI ORAL ABSTRACT SESSIONS
13 SESSIONS 108 ABSTRACTS

EDUCATION AWARDS
14x EARLY CAREER 10x DEVELOPING NATIONS

TOTAL NUMBER OF COUNTRIES IN WHICH MEETING WAS COVERED
123

UNIQUE ONLINE VISITORS FEATURING WCLC COVERAGE
67,600,000,000
The IASLC has formed an alliance with the Global Lung Cancer Coalition (GLCC), Guardant Health, and AstraZeneca to accelerate the pace of lung cancer survival worldwide. This collaborative effort allows scientists, specialists, advocates, and patients to break the barriers limiting progress with a goal to double 5-year survival rates of lung cancer by 2025. Together, we have identified three key areas of focus that will allow us to drive innovation and improvements in the field and, ultimately, to improve the lives of lung cancer patients worldwide.

**Pillar 1**
Increasing lung cancer screening and early diagnosis rates

**Pillar 2**
Accelerating the delivery of innovative therapies

**Pillar 3**
Improving the quality of care to provide the best possible outcomes for patients

The Lung Ambition Alliance was pleased to welcome five new Project Partners to the Alliance in 2020:

- Merck
- Bristol Myers Squibb
- Genentech
- Lilly Oncology
- Novartis
Lung Ambition Alliance Flagship Scientific Projects

The Lung Ambition Alliance (LAA) currently oversees multiple groundbreaking scientific projects that bring together oncologists, radiologists, surgeons, pulmonologists, researchers, patients, advocates, and pharmaceutical companies from around the world. These projects span a wide range of topics, from updating the current TNM Staging System, to investigating tumor response, to neoadjuvant therapies that help drive innovation and collaboration in the field of lung cancer. Learn more about all of the LAA Projects.

› MPR: Major Pathologic Response

Before undertaking the MPR project by the IASLC and the LAA, there were no established guidelines for processing and evaluating resected lung cancer specimens and there was a lack of precise definitions for the degree of pathological response following neoadjuvant therapy. These recommendations were published in the *Journal of Thoracic Oncology*. The IASLC has begun working on step two of the MPR project, which aims to determine a global cadre of pathologists’ reproducibility of histological MPR and CPR assessments in surgical resection specimens of lung cancer patients treated with neoadjuvant immune checkpoint inhibitors with and without chemotherapy by implementing the published IASLC recommendations. Each of these steps will help the IASLC and LAA establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR), in surgical resection specimens following neoadjuvant therapies as predictors and surrogate markers of long-term clinical benefit in patients with resected stage I to III lung cancer. Learn more about the MPR project.

› Early Lung Imaging Confederation (ELIC):

Effective screening is critical to detecting and diagnosing lung cancer early and thus increasing patient survival. The Early Lung Imaging Confederation (ELIC) is an international alliance of collaborating individuals and institutions who share a vision to develop a globally distributed, privacy-secured, lung cancer imaging database, and computational analysis environment. The main goal of ELIC is to support the development of deep learning methods or artificial intelligence approaches to detect early lung cancer and other diseases using thoracic CT images. This work will allow medical professionals to characterize small pulmonary nodules and surrounding structures, and to measure responsiveness to therapeutic interventions. The IASLC is currently facilitating the uploading of cases into the database and had approximately 600 cases uploaded by December 2020. Learn more about the ELIC project.

› TERAVOLT: Supporting a global effort to understand the impact of COVID-19 on thoracic malignancies

The COVID-19 pandemic has presented unique challenges for treating thoracic malignancies. To increase the understanding of COVID-19 as it relates to lung cancer and other thoracic malignancies, the IASLC, on behalf of the LAA, is pleased to support TERAVOLT, a global consortium that was created to understand the impact of COVID-19 on patients. Learn more about the TERAVOLT Project.
Staging: Improving Lung Cancer Staging through International Collaboration

For more than 20 years, the IASLC Lung Cancer Staging Project has provided valuable recommendations for the TNM classification of lung cancer—jointly published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The IASLC is currently gathering data to inform the 9th edition of the TNM Staging System, which for the first time, will include new data elements such as gene mutations, fusions, number alterations, and protein expression levels. The goal of these additional tumor characteristics is to significantly enhance the accuracy of the Staging System, leading to more precise treatment regimens and increased patient survival. As of November 2020, the following number of cases have been collected from more than 20 countries:

- 54,789 Lung Cancer Cases
- 436 Mesothelioma Cases
- 7,183 Thymic Malignancies Cases

We need your help! Submit data to the 9th edition of the Staging Project today! Your contribution will help us to build the most robust global dataset for lung cancer, mesothelioma, and thymic malignancies.

For more information on the IASLC’s Staging Project or how to contribute data, please visit www.IASLC.org/staging.
LUNG CANCER
CONSIDERED

with Dr. Stephen Liu and Dr. Narjust Duma
an IASLC Podcast

Lung Cancer Considered has released more than 50 podcasts which have been viewed and streamed more than 17,000 times globally, since its inception in 2019. Lung Cancer Considered features the researchers, healthcare professionals, patients, and advocates who are making a difference in the advancement of the study and treatment of thoracic malignancies. We’re happy to announce new hosts, Dr. Narjust Duma and Dr. Stephen Liu, who will bring a new perspective to the podcast series.

Listen here and join in the conversation.
Other IASLC Scientific Projects

- **Molecular Testing Survey**
  In January 2020, the results of the IASLC Global Survey on Molecular Testing in Lung Cancer were published in the *Journal of Thoracic Oncology*. The purpose of this survey was to assess the current prevalence and practice of molecular testing and to identify barriers or gaps that exist and thus improve molecular testing globally. A total of 2,537 respondents from 102 countries participated in the survey, including those who test and treat patients, those who perform and interpret assays, and those who acquire tissue for testing. The results showed that awareness and adoption of molecular testing for lung cancer are still relatively low around the world. Although results varied by region, the five most frequent barriers cited in all regions were cost, quality and standards, access, awareness, and turnaround time. The findings of this survey can inform the development of solutions that can be applied broadly and those that can be tailored to specific regions. The IASLC is currently developing educational initiatives aimed to improve technical knowledge and awareness of guidelines. Guidelines are being updated with state-of-the-art evidence-based practices. Learn more and read the entire survey.

- **Tobacco Control and Smoking Cessation**
  This year the IASLC Tobacco Control and Smoking Cessation Committee developed “Tobacco Control Moments” that were shared at the 2020 North America Conference on Lung Cancer. These short educational talks discussed how to incorporate delivering smoking cessation across the cancer care continuum, the importance of smoking cessation services in the era of telehealth, the integration of smoking cessation into lung cancer screening through clinical trials, and tobacco product updates and myth busters.

  In February 2020, the IASLC also held a workshop in conjunction with the FDA and AACR based on the 2019 IASLC Declaration on Tobacco Cessation after Cancer Diagnosis. This workshop brought together thought leaders and the public to discuss the importance of incorporating smoking status as a required data element for all prospective clinical trials as well as the need for trial design to effectively incorporate tobacco cessation interventions.

- **Quality Oncology Practice Initiative (QOPI)**
  In 2020, the IASLC expanded its partnership with the American Society of Clinical Oncology (ASCO) and the QOPI program in Spain. We are now closely working with the Foundation for Excellence and Quality in Oncology (ECO) to improve the quality of lung cancer care across Spain. The IASLC also continued our efforts in Brazil and expect to build upon these partnerships in the coming years. Learn more about the QOPI project.

- **Diagnostic Immunohistochemistry Atlas**
  This year, the IASLC Pathology Committee, led by the editorial group of Drs. Yasushi Yatabe, Alain Borczuk, Wendy Cooper, Sanja Dacic, Keith Kerr, Andre Moreira, and Ming Tsoa, developed the *Atlas on Diagnostic Immunohistochemistry* (IHC). This Atlas is an expansion on the JTO publication from 2019 and serves as a guidebook for pathologists as they continue to improve the diagnosis of thoracic cancers through IHC. Order your IHC Atlas.

- **CancerLinQ**
  The IASLC is working collaboratively with ASCO to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC is contributing thought leadership and subject matter expertise to CancerLinQ, including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content. Learn more about CancerLinQ and stay tuned for the IASLC’s research from data in 2021.

- **Impacts of COVID-19 on International Lung Cancer Clinical Trials Project**
  The COVID-19 pandemic has impacted cancer clinical trials. Although we have studies focused on the impact of the pandemic on new cancer diagnoses and cancer clinical trial participation in general, none have focused specifically on the impact of COVID-19 on lung cancer clinical trials. It is important for the lung cancer community to understand the impacts of COVID on lung cancer studies and identify measures to mitigate those impacts in order to continue to move the science of lung cancer treatment forward, and to improve patient outcomes.

  The purpose of this study was to determine the extent to which lung cancer clinical trials have been impacted by the pandemic across the whole spectrum of care in all regions of the world and how those impacts have been mitigated. Additionally, the study will identify other mitigation measures, and potentially modify the structure of the clinical trials process to increase patient and physician participation to expedite the expansion of effective treatment options for lung cancer patients. This survey will engage clinicians, industry partners, and regulatory bodies and will be released in early 2021.
**JTO & JTO CRR**

**Serving the Lung Cancer Community Through Cutting-Edge Publications**

**JOURNAL OF THORACIC ONCOLOGY**

The *Journal of Thoracic Oncology* (JTO), the IASLC’s official journal, has become the field’s authoritative publication for education and information related to all aspects of thoracic malignancies. The JTO includes original research, reviews, and opinion pieces, and reaches a diverse audience, including epidemiologists, statisticians, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology. During the COVID-19 pandemic, the JTO rapidly reviewed and published articles that informed expert decision-making, including the first article on pulmonary pathology of lung cancer patients with COVID-19.

The JTO’s influence on the field is represented by its increased impact factor, which has climbed dramatically in recent years. From having an impact factor of 6.595 in 2016, the JTO’s impact factor rose to 12.460 in 2018 and then again to 13.357 in 2019. Additionally, it ranks 11th out of all oncology journals and 3rd out of all respiratory system publications.

**JTO RANKINGS:**

**ONCOLOGY JOURNALS**

11 OUT OF 244 IN 2019

**RESPIRATORY JOURNALS**

3 OUT OF 64 IN 2019

**JTO Impact Factor increases to 13.357!**
“JTO CRR’s success and continued growth in its first year is a reflection of the support of our readers, authors, and reviewers. The journal will publish monthly starting in 2021 to accommodate the many meritorious articles it is receiving. This open access journal broadens the reach of the IASLC throughout the world, offering unfettered access to the thoracic oncology community.”

-Alex A. Adjei, MD, PhD
Editor-in-Chief

JTO CLINICAL AND RESEARCH REPORTS

JTO Clinical and Research Reports (JTO CRR) successfully launched in 2020. This journal complements the JTO by offering authors a gold open-access publication option. JTO CRR published four issues that included more than 50 articles in 2020. Based on the abundance of quality research articles, JTO CRR will begin publishing monthly starting in January 2021. Learn more about the JTO CRR.

JTO 2020 ARTICLE DOWNLOADS

2,883,298

JTO CRR 2020 ARTICLE DOWNLOADS

104,994
Advances in the care of patients with lung cancer and novel treatment options have grown exponentially over the past decade. The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the organization. We hope to increase the pace of knowledge sharing and advancements in care by offering the patient advocate audience opportunities to:

› Attend conferences;
› Form relationships with researchers and care providers;
› Lend their voices, sitting side-by-side with researchers and members of the care team; and
› Share their perspectives and experiences.

The IASLC strives for inclusivity and offers multiple opportunities to support individuals on their journeys as patient research advocates.

**IASLC Supportive Training for Advocates on Research & Science (STARS)**

The IASLC STARS program aims to increase the number of patient research advocates (PRAs) equipped to provide accurate scientific translation in their groups for patients with lung cancer and their caregivers and to provide the patient perspective for lung cancer research and policy.

In its second year, and amid the COVID-19 pandemic, the 6-month program went fully virtual. To ensure maximum knowledge sharing and opportunities to network, STARS partnered with Research Advocacy Network (RAN). The RAN platform allowed PRAs and Mentors to access various learning modules and then come together weekly to discuss and collaborate. STARS was developed by the IASLC in collaboration with lung cancer research advocates and patient advocacy nonprofits.

**2020 STARS Contributing Organizations**
The IASLC is proud to support the following individuals in the 2020 IASLC STARS Program

**STARS MENTORS**

Andrew Ciupek  
USA

Ivy Elkins  
USA

Lillian Leigh  
AUSTRALIA

Melissa Crouse  
USA

Merel Hennink  
NETHERLANDS

Sue McCullough  
AUSTRALIA

**PATIENT RESEARCH ADVOCATES**

Anita McGrath  
AUSTRALIA

Anne Marie Cerato  
CANADA

Caleb Egwuenu  
NIGERIA

Christine Qiong Wu  
CANADA

Debra Violette  
USA

Diane Colton  
CANADA

Erika Hlavacek  
USA
PATIENT RESEARCH ADVOCATES CONTINUED

Kimberly Lester
USA

Laura Book
USA

Lily Huang
NEW ZEALAND

Lisa Briggs
AUSTRALIA

Terri Conneran
USA

Tom Wood
AUSTRALIA

Tomma Hargraves
USA

2020 STARS Sponsors

AMGEN Oncology

Bristol Myers Squibb™

Genentech
A Member of the Roche Group

Lilly Oncology

CANCER CARE TEAM AWARDS

The IASLC Cancer Care Team Award is a prestigious award which aims to honor and recognize outstanding patient care served by multidisciplinary teams working together. Nominations are accepted from all over the world by individual patients with lung cancer and/or their caregivers/care partners. The IASLC is proud to honor the following winning teams of the 2020 IASLC Cancer Care Team Award:

OVERALL Winner: North America
Mount Sinai Hospital
New York, New York
Andrea Wolf, MD
Marissa Senise, NP
Jorge Gomez, MD
Jessica Fernandez, PA
Thomas Marron, MD, PhD
Stephanie Lehrman, LCSW
Kenneth Rosenzweig, MD

Latin America
Instituto De Oncologia ‘Angel H. Roffo’
Buenos Aires, Argentina
Monica Castro, MD
Mara Bonet, MD
Carolina Gabay, MD
Pablo C. Morgado, MD

Europe
Klinikum Würzburg Mitte
Würzburg, Germany
Jens Kern, MD
Jürgen Wolf, PhD
Gabi Hautsch, RN
Danjouma Cheufou, MD

Asia/ROW
Beilinson Hospital - Rabin Medical Center
Petach Tikva, Israel
Alona Zer, MD
Tal Danin Ovad, BA
Hiba Reches, RN

2020 IASLC Cancer Care Team Award Video
The IASLC is a proud partner and founder of the LCAM Coalition. The Coalition is composed of more than 40 nonprofit organizations with a focus on lung cancer. Each year in November, the Coalition unites to generate public awareness about the impact of lung cancer, promote events of the Coalition partners, and share available resources on potentially life-saving treatment options.
WEBINARS

In response to the COVID-19 pandemic, the IASLC conducted a series of CME-accredited webinars providing a global forum for multidisciplinary perspectives on the diagnosis and management of lung cancer within the COVID-19 environment.

2020 IASLC Webinars:

COVID-19

› Impact of COVID-19 on Treatment of Lung Cancer Patients with Local and Locoregional Disease. (April 28, 2020)
› Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic (April 29, 2020)
› Impact of COVID-19 on Treatment of Lung Cancer Patients with Local and Locoregional Disease. (May 11, 2020)
› Supportive Care for Lung Cancer Patients During COVID-19 (December 8, 2020)

Other topics

› Highlights of ASCO (July 31, 2020)
› Cancer Drug Development in the Era of Precision Medicine (November 2, 2020)

ATTENDEES BY CONTINENT

48.1% North America
15% Asia
25.5% Europe
11.3% Rest of World

Dr. Sonam Puri and Dr. Jaskaran Sethi
Salt Lake City, Utah
ATTENDEES BY PRIMARY SPECIALTY

Medical Oncology 26.8%
Radiation Oncology 17.6%
Thoracic Surgery 10.5%
Other 8.3%
Pulmonary Medicine 7.9%
Advocacy 5.6%
Biotech/Pharmaceutical Industry 5.6%
Cancer Research/Basic Sciences 5.4%
Pathology 4.1%
Nursing 3.6%
Pharmacy 2.1%
Resp. Therapy/Physiotherapy 1.1%
Diagnostic Radiology 0.6%
Biostatistics 0.3%
Smoking Cessation 0.2%
Hematology 0.1%

ATTENDEES BY COUNTRY

1,736
TOTAL ATTENDANCE
619
IASLC MEMBERS

Click to Access Recorded Webinars
With the advent of the all-virtual era, the IASLC worked to provide opportunities to bring corporate partners and our global audience together. There are so many ways to partner with the IASLC—by sponsoring an upcoming meeting, project, or activity. We would like to extend a thank you to our top corporate partners of 2020.

To learn more about becoming a Corporate Supporter of the IASLC, please contact us at corporaterelations@iaslc.org.
The International Lung Cancer Foundation aims to accelerate the pace of thoracic malignancy research, to inspire researchers to focus their careers on lung cancer, and to reduce the worldwide lung cancer mortality rate.

Donations from patients, caregivers, and those individuals passionate about accelerating the pace of lung cancer research, as well as from our organizational and corporate partners, directly fund our Research Awards. These Research Awards provide early-career researchers with vital funding opportunities, fostering tomorrow’s lung cancer visionaries and achieving milestones in patient care.

**Honoring a Special 2020 Contribution**

In early 2020, the ILCF received a generous gift of $200,000 from Dr. Fred Hirsch. “I’ve dedicated my career to eradicating lung cancer,” Hirsch stated. “Over the last decade, and particularly within the last few years, we’ve seen great momentum with treatment, and I believe that for this momentum to continue, we need to support research now more than ever. I am proud to support the ILC Foundation, especially knowing that my contribution will directly fund research and help to develop the next generation of lung cancer specialists.”

Dr. Hirsch’s gift will help the ILCF inspire hope through research by funding four one-year Research Awards.

**2020 Fundraising**

At the ILCF, our 2020 fundraising got off to a great start. Three IASLC members and stage I lung cancer survivors—Christie Malnati, Sandy Shea, and Kathy Weber—came together as “Team Hope” to participate in the 2020 Lung Cancer Survivors Super Bowl Challenge, part of the Chris Draft Family Foundation. Through the Super Bowl Challenge, Team Hope raised $11,731.50! The ILCF was excited and grateful to be selected as the beneficiary of their fundraising.

One goal of our 2020 fundraising strategy was to increase the number of individual donations by making donating easier. By including an option to donate in the meetings registration process and in the membership renewal process, as well as by making our online donation process easier, we generated just over $54,000 from 657 donors—far surpassing our previous high number of individual donors of 248 in 2018.
2020 Research Awards

In 2020, the Foundation awarded 11 Research Awards totaling just over $1.1 million. This year’s award recipients are working across the globe—in Belgium, Canada, Ireland, Italy, Spain, and the United States—to eradicate lung cancer and other thoracic malignancies. Our Research Awards program is made possible by individual donations from people like you and by Foundation partners and organizations.

2020 Foundation Partners

2020 Funding Partners

ILCF BOARD OF DIRECTORS

Drs. Andrea Bezjak, Heather Wakelee, and Joan Schiller serve as leaders to both the scientific and IASLC community.

At the 2019 World Conference on Lung Cancer in Barcelona, the ILCF celebrated the global recipients of ILCF Research Awards. Pictured from left: Dr. Warren Naselsky, University of Maryland School of Medicine (USA); Dr. Hanbo Chen, University Medical System Amsterdam (Europe); Dr. Roberto Ferrara, I.R.C.C.S. National Cancer Institute (Europe); Dr. Ashwin Somasundaram, UPMC Hillman Cancer Center (USA); and Dr. Tejas Patil, University of Colorado (USA).
2020 Donors

$200,000
Fred R. Hirsch

$5,000
David and Diane Gandara
Li Xu

$2,500-$4,999
Ray and Hilda Osarogiagbon

$1,000-$2,499
AnnMarie Priest
David Carbone
David Spigel
Gregory and Martha Raber
Gregory P Galanos
Paul A. Bunn, Jr.
William Pao

$500-$999
Alain Charles Borczuk
Dave Mesko
Heather Wakelee
Julie Brahmer
Lauren K. Fisher
Martin Edelman
Michael J Boyer
Paul Van Schil
Robert Pirker
Roy S Herbst
Skaidrius Miliauskas
Suresh Ramalingam
Xueming Qian

$200-$499
Alfredo Lopez
Charles Rudin
Corey Langer
David Ball
David James Group
David S. Gierada
Eric Bernicker

$100-$199
Alejandro Calvo
André de Fusco
Andrea Borondy-Kitts
Anna Tomiak
Anne Marie Robertson
Antoinette Wozniak
Art Mallette
Betty Tong
Bruce Dunbar
Camille Nizet
Charles Baum
Christian Couture
Cristina Fernández
Daphna Gelblum
Douglas Arenberg
Ebenezer Kio
Edgardo Santos
Eric Vallieres
Erik Thunnissen
Etsuo Fujita
Francisco Orlandi Jorquera
Gabrielle Goodman

$50-99
Aki Katarina Kobayashi
Andy Saylor
Angela De Palma
Apurna Jegannathan
Bihong Zhao
Calvin Sze Hang Ng
Carla Azevedo
Carla Weenink
Carlo Genova
Carolyn Presley
Choon-Taek Lee
Clarissa Mathias
Craig Underhill
David Barnes
Denise Aberle
Diane Colton
Don Siegel
Donald and Susan Mackowiak
Dong Kwan Kim
Dwight H Owen
Eeva-maija Nieminen
Eldamarina Mascarenhas
Elisabeth Brambilla
Eugene & Debra Novello
Fall River Employee Benefits
Ferdinando Cerciello
Fiorella Calabrese
Florence Siu Ting Mok

$500
George A. Eapen
Gregory M.M. Videtic
Hossein Borghaei
Jeanette Hood
Junichi Shimizu
Kazuhiko Shibata
Keunchil Park
Kristin Richeimer
Luka Brcic
Maria Amelia Brilhante Almeida
Maria Catherine Pietanza
Michael Jones
Ming Sound Tsao
Misako Nagasaka
National Storage Affiliates
Quincy Chu
Rui Haddad
Stephen Graziano
Stephen Lam
Susie Grant Owen
The David D Ring Jr Family

$1,000
Giannis Mountzios
Giovanni L. Carboni
Heidi Nafman-Onda
Hiromasa Yamamoto
Hongxu Liu
Hua Cheng
Iman Abdalla
Jacek Kowalski
Jacques Tabacof
James R. Jett
Jason Porter
Javier Montoro
Jennifer Wing
Jichiro Sasaki
Jill Forrest
Jo Monsen
John & Holly Bohman
John Doll
Joy Curzio
Justin, Krystina, & Kameron Mackowiak
Karen Reckamp
Keith Cengel
Ken Uchibori
Krassimir Koynov
Krislein Tsuboi
Leora Horn
Leanne Azevedo
Luis E. Raez
Lucas Krieger
Makenzi Evangelist
Marcia Horn
Mari Mino-Kudson
Marilyn Ramey
Markus Tiemann
Mary Jo Fisher
Masahiro Fukuoka
Matteo Tuschi
Matthew Steliga
Michael Lanuti
Michael Rabin
Minako Sumi
Munther I. Ajlouni
Neal Ready
Paul Walker
Peggy Dennis
Philip Bonomi
Philippe Joubert
Ruben Khaw Li
Satoshi Muto
Sergio Sanchez
Sergio Santillana
Shirish Gadgeel
Stephen Veach
Sukhmani Padda
Takahisa Yamazaki
Takashi Suzuki
Takuya Aoki
Terufumi Kato
Tetsuya Mitsumori
Tom John
Turja Chakrabarti
Umberto Malapelle
William Walsh
Yaron Shargall

$2,000
Aki Katarina Kobayashi
Andy Saylor
Angela De Palma
Apurna Jegannathan
Bihong Zhao
Calvin Sze Hang Ng
Carla Azevedo
Carla Weenink
Carlo Genova
Carolyn Presley
Choon-Taek Lee
Clarissa Mathias
Craig Underhill
David Barnes
Denise Aberle
Diane Colton
Don Siegel
Donald and Susan Mackowiak
Dong Kwan Kim
Dwight H Owen
Eeva-maija Nieminen
Eldamarina Mascarenhas
Elisabeth Brambilla
Eugene & Debra Novello
Fall River Employee Benefits
Ferdinando Cerciello
Fiorella Calabrese
Florence Siu Ting Mok

$1,000
Giannis Mountzios
Giovanni L. Carboni
Heidi Nafman-Onda
Hiromasa Yamamoto
Hongxu Liu
Hua Cheng
Iman Abdalla
Jacek Kowalski
Jacques Tabacof
James R. Jett
Jason Porter
Javier Montoro
Jennifer Wing
Jichiro Sasaki
Jill Forrest
Jo Monsen
John & Holly Bohman
John Doll
Joy Curzio
Justin, Krystina, & Kameron Mackowiak
Karen Reckamp
Keith Cengel
Ken Uchibori
Krassimir Koynov
Krislein Tsuboi
Leora Horn
Leanne Azevedo
Luis E. Raez
Lucas Krieger
Makenzi Evangelist
Marcia Horn
Mari Mino-Kudson
Marilyn Ramey
Markus Tiemann
Mary Jo Fisher
Masahiro Fukuoka
Matteo Tuschi
Matthew Steliga
Michael Lanuti
Michael Rabin
Minako Sumi
Munther I. Ajlouni
Neal Ready
Paul Walker
Peggy Dennis
Philip Bonomi
Philippe Joubert
Ruben Khaw Li
Satoshi Muto
Sergio Sanchez
Sergio Santillana
Shirish Gadgeel
Stephen Veach
Sukhmani Padda
Takahisa Yamazaki
Takashi Suzuki
Takuya Aoki
Terufumi Kato
Tetsuya Mitsumori
Tom John
Turja Chakrabarti
Umberto Malapelle
William Walsh
Yaron Shargall
IASLC BOARD OF DIRECTORS

OFFICERS

Tetsuya Mitsudomi
President
Japan

Heather Wakelee
President-Elect
United States

Giorgio Scagliotti
Past-President
Italy

Suresh Ramalingam
Treasurer
United States

Enriqueta Felip
Secretary
Spain

Dave Mesko
Chief Executive Officer
United States

MEMBERS

Andrea Bezjak
Canada

Julie Brahmer
United States

Anne Fraser
New Zealand

Roy Herbst
United States

Clarissa Mathias
Brazil

Yuko Nakayama
Japan

Masayuki Noguchi
Japan

Nir Peled
Israel

Erik Thunnissen
The Netherlands

Paul Van Schil
Belgium

James Yang
Taiwan

Caicun Zhou
China
IASLC STAFF

Dave Mesko
Chief Executive Officer

AnnMarie Priest
Chief Development Officer and Executive Director, ILC Foundation

Kristin Richeimer
Chief Experience Officer

John Skadow
Chief Financial Officer

Tessa Baxter
Foundation Coordinator

Kirsten Black
Educational Programs Manager

Becky Bunn
Senior Advisor, Scientific Relations

Casey Connolly
Scientific Affairs Coordinator

Tammy Curry
Administrative Assistant

Jill Daigneault
Program Manager

Beth Dobos
Web Content Administrator

Kathy Doherty
Director, Human Resources

Brianda Duarte
Scientific Affairs Coordinator

Ken Harrell
Member Records Administrator
Kristin Ito  
Associate Director, ILC Foundation and Patient Advocacy

Stephanie Lenhart  
Accounting Manager

Sara Lindsey  
Administrative Assistant

Katie Maher  
Member Experience Coordinator

Jan Mazotti  
Associate Director, Communications and Marketing

Abigail Metzger  
Corporate Relations Coordinator

Karen Muth  
Executive Assistant and Board Liaison

Anne Orban  
Marketing Coordinator

Aubrey Shoe  
CME and Education Coordinator

Jeanette Stensgaard  
Conference Planning Manager

Mary Todd  
Managing Editor, JTO & JTO CRR

Jennifer Vitek  
Program Development Coordinator

Kelsey Wood  
Associate Director, Member Experience

Murry Wynes  
Senior Advisor, Scientific Affairs

Kexin Yu  
Accountant